Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Tue, 23.12.2025
Formycon AG
Press Release // December 23, 2025
FDA approves another interchangeable Ranibizumab Biosimilar, Nufymco® – Strengthening US Presence with Zydus as Commercialization Partner
FDA approves Biologics License Application (BLA) for additional ranibizumab biosimilar under the trade name Nufymco®
Zydus becomes commercialization partner for Nufymco® [ … ]
Tue, 09.12.2025
Formycon AG
Presse Release // December 09, 2025
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for a successful lau [ … ]
Thu, 04.12.2025
Formycon AG
Presse Release // December 04, 2025
Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region
Planegg-Martinsried, Germany / Amman, Jordan – Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into an exclusive licensing and suppl [ … ]
Mon, 24.11.2025
Formycon AG
Press Release // November 24, 2025
NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy
Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) and NTC s.r.l. (“NTC”) jointly announce that Klinge Biopharma GmbH (“Klinge”), the exclusive owner of the global commercialization rights of Formycon [ … ]
Thu, 20.11.2025
Formycon AG
Company Name:
Formycon AG
ISIN:
DE000A1EWVY8
Reason for the research:
Q3 results/FYB208 reference product
Recommendation:
Buy
from:
20.11.2025
Target price:
€53
Target price on sight of:
12 months
Last rating change:
-
Analyst:
Simon Scholes
First Berlin Equity Research has published a research update on Formycon AG (ISIN [ … ]
Thu, 20.11.2025
Formycon AG
Press Release // November 20, 2025
Ranibizumab Biosimilar Epruvy® launched in Germany
Sandoz commercializes Epruvy®1 in innovative pre-filled syringe (PFS) and vial presentation in Germany under license from Bioeq AG
The PFS delivery system represents a key advancement combining biosimilar development excellence with customer-friendly design [ … ]
Mon, 17.11.2025
Formycon AG
Press Release // November 17, 2025
Milestone achieved with FYB208: Biosimilar candidate for Dupixent® (dupilumab) as another growth driver in Formycon's portfolio
Important preclinical milestone Technical Proof of Similarity (TPoS) demonstrates high analytical comparability of FYB208 to reference drug
Strong in vitro data support cost-effe [ … ]
Thu, 13.11.2025
Formycon AG
Press Release // November 13, 2025
Formycon publishes nine-month results and confirms guidance – Pipeline progress and strong partnerships drive fiscal year 2025
Guidance for 2025 confirmed – Revenue and earnings development in line with expectations
FYB202 (Stelara®1 biosimilar): Market penetration in the US and Europe continues
Significant [ … ]
Thu, 30.10.2025
Formycon AG
Press Release // October 30, 2025
Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
Planegg-Martinsried, Germany – Formycon AG (FSB: FYB, Prime Standard, „Formycon“) plans to publish its Nine-Month Results 2025 on November 13, 2025. The Management Boar [ … ]
Tue, 21.10.2025
Formycon AG
Press Release // October 21, 2025
Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe
Innovative pre-filled syringe (PFS) with high standards for intravitreal injections1 offers improved handling, high dosing accuracy and greater convenience for applicants
Teva Pharmac [ … ]
